<?xml version="1.0" encoding="UTF-8"?>
<p id="p0175">While IL-6 is elevated in about 33% of mild COVID-19 patients, 76% of severely affected patients exhibit elevation of this pro-inflammatory cytokine. In fact, COVID-19 patients characterized as having severe disease have corresponding escalations of IL-6, TNF-α, IL-2, MCP-1, MIP-1A, IL-10, IL-7, and G-CSF, especially in ICU patients [
 <xref rid="bb0005" ref-type="bibr">1</xref>]. Further, evidence of cytokine release syndrome (CRS) or ‘storm’ was confirmed by an escalation in IL-6 levels [
 <xref rid="bb0300" ref-type="bibr">60</xref>] in conjunction with inadequate levels of the negative regulatory suppressor of cytokine signaling 3 (SOC 3) [
 <xref rid="bb0305" ref-type="bibr">61</xref>].
</p>
